{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:59:44Z","timestamp":1792627184268,"version":"4.5.0"},"reference-count":18,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Daratumumab is an anti-CD38 monoclonal antibody used in the treatment of myeloma and other related disorders. To mitigate the risk of infusion related reactions with IV Daratumumab the product monograph suggested a slow administration schedule that extends over several hours.\n                      <jats:sup>\n                        <jats:xref ref-type=\"bibr\">1<\/jats:xref>\n                      <\/jats:sup>\n                      This leads to a significant burden for the outpatients\u2019 treatment administration units and indirect costs to the patients such as time toxicity. Time toxicity is the time spent coordinating care and making frequent visits for follow-up and treatment.\n                      <jats:sup>\n                        <jats:xref ref-type=\"bibr\">2<\/jats:xref>\n                      <\/jats:sup>\n                      In 2020 the COLUMBA trial\n                      <jats:sup>\n                        <jats:xref ref-type=\"bibr\">3<\/jats:xref>\n                      <\/jats:sup>\n                      demonstrated that subcutaneous Daratumumab has a similar efficacy and safety profile as intravenous Daratumumab with considerably less side effects.\n                      <jats:sup>\n                        <jats:xref ref-type=\"bibr\">1<\/jats:xref>\n                      <\/jats:sup>\n                      This retrospective study aims to document our local real-world experience with subcutaneous Daratumumab, with special emphasis on reducing time toxicity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with a plasma cell disorder over the age of 18 who had received at least one dose of subcutaneous Daratumumab between March 2022 and March 2023 were included. Data for this retrospective study was collected from Aria, which included: baseline patient demographics (gender, age); prior exposures to intravenous Daratumumab; and, whether a reaction to either intravenous or subcutaneous Daratumumab occurred. Descriptive statistics were used to summarize the data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 197 patients were included in the analysis. There were no recorded reactions to subcutaneous Daratumumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The results of our study were used to eliminate our facility's 3-h post-injection observation period. In the future we plan to publish another study on the cost efficiency of subcutaneous Daratumumab.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552241306741","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T03:15:51Z","timestamp":1736219751000},"page":"659-663","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Analysis of real-world safety, tolerability, and cost efficiency of Sub-Cutaneous administration of Daratumumab in Manitoba"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9999-258X","authenticated-orcid":false,"given":"Kaitlin","family":"Quinlan","sequence":"first","affiliation":[{"name":"CancerCare Manitoba"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2264-7801","authenticated-orcid":false,"given":"Marc","family":"Geirnaert","sequence":"additional","affiliation":[{"name":"CancerCare Manitoba"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Kotb","sequence":"additional","affiliation":[{"name":"CancerCare Manitoba"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vi","family":"Dao","sequence":"additional","affiliation":[{"name":"CancerCare Manitoba"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Minuk","sequence":"additional","affiliation":[{"name":"CancerCare Manitoba"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayne","family":"Kasian","sequence":"additional","affiliation":[{"name":"CancerCare Manitoba"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Rimmer","sequence":"additional","affiliation":[{"name":"CancerCare Manitoba"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,1,7]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220967738"},{"key":"e_1_3_2_3_2","unstructured":"The Oncology Pharmacist. Subcutaneous Isatuximab Administration by an On-Body Delivery System May Provide a More Convenient Option for Patients with RRMM. Link: https:\/\/jhoponline.com\/special-issues\/2022-year-in-review-multiple-myeloma\/19463-subcutaneous-isatuximab-administration-by-an-on-body-delivery-system-may-provide-a-more-convenient-option-for-patients-with-rrmm"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30070-3"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32128"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14180"},{"key":"e_1_3_2_7_2","article-title":"Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed\/refractory multiple myeloma","author":"Sanchez L","unstructured":"Sanchez L, Richter J, Cho HJ, et al. Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed\/refractory multiple myeloma. Ther Adv Hematol 2021 Jan 22;12. 1\u20138.","journal-title":"Ther Adv Hematol"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00940"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-020-03365-w"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01120-4"},{"key":"e_1_3_2_11_2","unstructured":"Daratumumab (DarzalexR) Product Monograph Janssen Inc. (October 25th 2019 edition)."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0120-2"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-128515"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1063144"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00801-1"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.2142.2142"},{"key":"e_1_3_2_17_2","first-page":"5018","article-title":"Real-World observations and practical considerations of subcutaneous daratumumab administration in multiple myeloma","volume":"138","author":"Bridget Kim E","unstructured":"Bridget Kim E, O'Donnell E, Branagan AR, et al. Real-World observations and practical considerations of subcutaneous daratumumab administration in multiple myeloma. Blood 23 November 2021; 138: 5018.","journal-title":"Blood"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0283-0"},{"key":"e_1_3_2_19_2","unstructured":"Myeloma Canada. Canadian Statistics for Multiple Myeloma. Retrieved from: https:\/\/myelomacanada\/ca\/en\/about-multiple-myeloma\/what-is-myeloma\/statistics"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241306741","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552241306741","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241306741","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T10:56:09Z","timestamp":1779274569000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552241306741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,7]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1177\/10781552241306741"],"URL":"https:\/\/doi.org\/10.1177\/10781552241306741","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,7]]}}}